Apreo Health is thrilled to announce a remarkable funding milestone, having raised $130,000,000 to accelerate the development of its groundbreaking clinical-stage solutions for patients suffering from severe emphysema, an advanced form of Chronic Obstructive Pulmonary Disease (COPD). This significant capital injection underscores the strong confidence investors have in Apreo Health’s mission to restore health and improve quality of life for patients facing debilitating respiratory conditions. Headquartered in Menlo Park, CA, the company is poised to utilize these funds to further advance its pioneering Apreo BREATHE Airway Scaffold, an investigational implant specifically designed to gently release trapped air in hyper-inflated lungs, thereby addressing one of the most critical aspects of emphysema management. Given that COPD was the second leading cause of death in the United States in 2018 and with over 8,000 emphysema-related deaths recorded in 2023, there is an urgent need for innovative treatments that can offer a tangible difference in patient outcomes. The new funding will enable Apreo Health to enhance its clinical investigations, expand research and development operations, and refine its device technology under strict Federal investigational guidelines. By bridging the gaps between cutting-edge medical device innovation and critical patient care needs, Apreo Health reaffirms its commitment to scientific excellence, integrity, and patient well-being. This landmark funding round not only fuels the continued progress of the Apreo BREATHE Airway Scaffold but also marks a transformative step towards establishing a new standard of care for lung disease sufferers across the country.
Apreo Health Secures $130M Series B Funding to Transform Emphysema Treatment with Innovative Airway Scaffold Solutions
Get the full Apreo Health company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Centricity WealthTech
Founded in January 2022, Centricity helps empower finance and investment professionals aspiring to establish their independent practices. The platform aims to deliver a comprehensive SAAS based investment management platform including digital transactional capabilities for a diversified product suite. Wealth management professionals prefer focusing on their clients’ interests and not their employers ever-changing priorities. Also, clients want stability and not a relentless institutional product push. We are looking to bring in consistency of the family office experience for a spectrum of investors across emerging affluent, affluent and high net worth categories. We are boutique by design and an institution by default.
$30.0M Series a
today
MigmaAI
Create, design and send on-brand emails in seconds.
$330.0K Pre-seed
today
Multiverse
Multiverse is the upskilling platform for AI and tech adoption. We’ve built a new model for transforming today’s workforce by combining expert human coaching with AI. Our learning drives real business impact and helps organisations close critical skills gaps - especially in data, AI and all things tech. We’ve already partnered with over 1,500 global organisations to transform their workforce through tech skills. Trusted by Microsoft, Mars, John Lewis Partnership and many more to upskill their team and unlock people’s potential and output. In 2022, we raised our $220m Series D funding - one of the largest venture rounds in EdTech history. We’re proud to be backed by some of the world’s biggest investors, including General Catalyst, Lightspeed Venture Partners and StepStone Group.
$70.0M Unknown
today
SWELL Sculpture Festival
SWELL Sculpture Festival (SWELL) is a multifaceted arts organisation that connects people, art, and place, based in Currumbin, Gold Coast, Queensland. Since 2003 SWELL has exhibited 873 Sculptures in the main exhibition on Currumbin Beach with a portfolio value worth $15.5M.
$5.5K Grant
today
Parcel Health
Healthcare and pharmacies' supply chain runs on expensive plastic. Billions of units of disposable, single-use supplies and packaging — most of it never questioned, never redesigned, never replaced. Paid for at a premium to budgets and to the environment. Until now. Parcel Health is reimagining healthcare supplies, creating products that can protect people and preserve the planet, all at an affordable price point. Tully Tube® is the world's first and only paper pill bottle that meets U.S. regulatory requirements. It is trusted by leading hospital health-systems like Dartmouth-Hitchcock Health System, Allegheny Health Network, and Wellstar Health System. This is just the beginning. Parcel Health is building a future where healthcare supplies are safer for patients, better for the planet, and easier on budgets.
$1.2M Seed
today
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  equipifi United States | Series b | $34.0M | today |
| 2 |  ANELLO Photonics United States | Series b | $25.0M | 1d ago |
| 3 |  Forest United States | Series b | $23.0M | 1d ago |
| 4 |  EnteroBiotix United Kingdom | Series b | $23.9M | 1d ago |
| 5 |  Fractile United Kingdom | Series b | $220.0M | 1d ago |